How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/refractory-peripheral-t-cell-lymphoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Refractory peripheral T-cell lymphoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Refractory peripheral T-cell lymphoma (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Refractory peripheral T-cell lymphoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Ontak	E7777	Eisai	CD25-directed Cytotoxin	Interleukin-2 receptor	1999-01-01
Ontak	DENILEUKIN DIFTITOX	Eisai	CD25-directed Cytotoxin [EPC]	Interleukin-2 receptor	1999-01-01
Ontak	Ontak	The University of Texas Health Science Center at San Antonio		Interleukin-2 receptor
Darvias	DARINAPARSIN	Solasia Pharma K.K

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Eisai · 2 drugs in Refractory peripheral T-cell lymphoma
Solasia Pharma K.K · 1 drug in Refractory peripheral T-cell lymphoma
The University of Texas Health Science Center at San Antonio · 1 drug in Refractory peripheral T-cell lymphoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Refractory peripheral T-cell lymphoma:

Cite this brief

Drug Landscape (2026). Refractory peripheral T-cell lymphoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/refractory-peripheral-t-cell-lymphoma. Accessed 2026-06-10.

Refractory peripheral T-cell lymphoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing